A Randomized, Open-Label, Single-Dose, 3-Period Crossover Study to Describe the Pharmacokinetic Parameters of BLI-489 and Piperacillin When Administered Simultaneously Compared to When Each is Administered Alone.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs BLI 489; Piperacillin
- Indications Bacterial infections
- Focus Pharmacokinetics
- 18 Jul 2009 Actual end date Jul 2009 added as reported by ClinicalTrials.gov.
- 18 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2009 Additional lead trial centre and location (Philadelphia, USA) identified as reported by ClinicalTrials.gov.